Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Researchers find promising drug for preventing serious complications of diabetes


Results reported in Nature Medicine

Opening up the possibility of a new approach to the treatment of diabetes, researchers have shown in animal studies that a drug long available in Europe can simultaneously block three of the major biochemical pathways responsible for the blood-vessel damage that causes serious diabetic complications.

Dr. Michael Brownlee of the Albert Einstein College of Medicine was the senior researcher for the international consortium that carried out the study, which appears in the current issue of Nature Medicine.

Research over the past 30 years has identified four biochemical pathways by which diabetes injures blood vessels - damage that makes diabetes the leading cause of blindness, kidney failure, heart attacks and nontraumatic amputation of legs in the U.S. In this study, from the Einstein Diabetes Research Center, the drug benfotiamine completely blocked three of those pathways when tested in diabetic rats, animals often used as models for studying the disease. Benfotiamine is a synthetic derivative of thiamine (vitamin B1) and has been available for more than a decade in Germany. It is prescribed there for treating diabetic neuropathy, sciatica and other painful nerve conditions but has never been tested in placebo-controlled, double-blind clinical trials.

In people with diabetes, all cells are bathed in blood that contains elevated levels of glucose. Most cells still manage to keep their internal glucose at normal levels. But certain cells - particularly endothelial cells that line arteries and the capillaries of the retina and kidney - are unable to regulate glucose and instead develop high internal levels of the sugar, which they can’t completely metabolize. As a result, glucose-derived "intermediate" metabolic products accumulate inside these cells, where they activate pathways of cellular damage that can eventually lead to blindness and other complications.

Dr. Brownlee and his colleagues focused on two glucose-derived intermediates that activate three of the damaging biochemical pathways. They knew that both of these metabolic compounds (fructose-6-phosphate and glyceraldehyde-3-phosphate) are the end products of another biochemical pathway mediated by an enzyme called transketolase.

By boosting transketolase’s activity, the researchers reasoned, they might be able to reverse this pathway - essentially converting the two damage-triggering glucose metabolites into harmless chemicals and preventing all three damaging biochemical pathways from being activated. They also knew that transketolase, like many enzymes, depends on a cofactor for its activity - in this case thiamine.

In preliminary studies involving arterial endothelial cells, adding standard thiamine boosted transketolase’s activity by only 20 percent, so the researchers looked around for a more potent form of thiamine. Dr. Brownlee’s German colleagues suggested benfotiamine, a fat-soluble thiamine derivative.

"By pure serendipity, it turned out that benfotiamine boosted the activity of the enzyme transketolase by 300 to 400 percent - something we never could have predicted based on benfotiamine’s chemical structure," says Dr. Brownlee, who is professor of medicine and of pathology, and the Anita and Jack Saltz Professor of Diabetes Research at Einstein.

As reported in the Nature Medicine paper, benfotiamine successfully blocked all three major destructive biochemical pathways in experiments with arterial endothelial cells. Next, the researchers treated diabetic rats with benfotiamine and then examined their retinal tissue. (For comparison, they also examined the retinas of control diabetic rats and normal rats.)

Chemical analysis showed that all three biochemical pathways had been "normalized" in the benfotiamine-treated diabetic rats so that their retinas were biochemically identical to the retinas of normal rats. The drug also prevented diabetic retinopathy in the animals, since microscopic examination revealed that the retinas of benfotiamine-treated diabetic rats were free of vascular damage.

No drug for preventing the complications of diabetes is currently available. Dr. Brownlee is applying to the U.S. Food and Drug Administration to test benfotiamine as an Investigational New Drug. Noting that drugs that produce impressive results in animals do not always work in humans, Dr. Brownlee says he is reasonably confident that benfotiamine will at least prove to be safe: "Benfotiamine has been used extensively in Germany for many years, and to my knowledge there are no reported side effects."

Dr. Brownlee cautions people with diabetes against taking thiamine supplements, however, noting that there is no evidence that thiamine can activate transketolase sufficiently to prevent complications of diabetes.

In addition to Dr. Brownlee and his Einstein colleagues, authors of the Nature Medicine paper included scientists from Germany, Italy, China and Japan. The research was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases, the American Diabetes Association and the Juvenile Diabetes Research Foundation.

Karen Gardner | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Advanced analysis of brain structure shape may track progression to Alzheimer's disease
26.10.2016 | Massachusetts General Hospital

nachricht Indian roadside refuse fires produce toxic rainbow
26.10.2016 | Duke University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Etching Microstructures with Lasers

Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.

This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Greater Range and Longer Lifetime

26.10.2016 | Power and Electrical Engineering

VDI presents International Bionic Award of the Schauenburg Foundation

26.10.2016 | Awards Funding

3-D-printed magnets

26.10.2016 | Power and Electrical Engineering

More VideoLinks >>>